Wellington Management Group LLP increased its position in shares of Haleon plc (NYSE:HLN - Free Report) by 49.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,152,490 shares of the company's stock after buying an additional 3,046,841 shares during the quarter. Wellington Management Group LLP owned 0.20% of Haleon worth $96,833,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Fortitude Family Office LLC bought a new position in shares of Haleon during the 3rd quarter worth approximately $28,000. Cultivar Capital Inc. bought a new position in Haleon in the second quarter valued at $40,000. Prospera Private Wealth LLC bought a new stake in Haleon during the 3rd quarter worth about $57,000. BOKF NA boosted its stake in shares of Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company's stock worth $58,000 after buying an additional 2,842 shares during the last quarter. Finally, Rothschild Investment LLC acquired a new position in shares of Haleon during the 2nd quarter worth about $60,000. Institutional investors and hedge funds own 6.67% of the company's stock.
Haleon Stock Performance
Shares of HLN stock traded up $0.02 on Tuesday, reaching $9.67. The stock had a trading volume of 6,431,284 shares, compared to its average volume of 5,337,325. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The firm has a market capitalization of $43.75 billion, a price-to-earnings ratio of 28.41, a P/E/G ratio of 2.92 and a beta of 0.28. The firm's 50-day moving average is $9.81 and its two-hundred day moving average is $9.49. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.
Wall Street Analyst Weigh In
HLN has been the topic of several analyst reports. UBS Group upgraded Haleon to a "strong-buy" rating in a report on Tuesday, October 1st. Morgan Stanley upped their price objective on Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a research note on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $10.95.
View Our Latest Report on HLN
Haleon Company Profile
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Further Reading
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
